0.08Open0.08Pre Close0 Volume3.08K Open Interest7.50Strike Price0.00Turnover600.89%IV118.44%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.1118Delta0.1052Gamma43.38Leverage Ratio-0.0540Theta0.0000Rho4.85Eff Leverage0.0006Vega
Poseida Therapeutics Stock Discussion
NEWS
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
NEWS
Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.
No comment yet